JAK of All Trades: Novel Off-Label Use of the Systemic JAK Inhibitor Upadacitinib As An Adjunct to Systemic Biologic Therapy for Various Immune-Mediated Inflammatory Diseases of the Skin

Combining two targeted systemic therapies (biologics and JAK inhibitors) may provide a more significant reduction in disease severity and improvement in quality of life (QoL); however, no rigorous studies have assessed such an approach. In this retrospective case series, we highlight the novel off-label use of UPA, a selective JAK1 inhibitor, as an adjunct to different systemic biologics for a variety of skin-related IMIDs.